|
V.TLT
|
Until recently Theralase invariably released their financials and...
|
|
V.TLT
|
in general there is no monotherapy for NMIBC that is remotely competitive...
|
|
V.TLT
|
Looking at more recent data, it seems that the 24 month CR rate of the...
|
|
V.TLT
|
I know a few competitor numbers: Adstiladrin 24 month CR = 4% N803/Anktiva...
|
|
V.TLT
|
As of October 16, 2023, 42 patients had been assessed at 450 days. Those 42...
|
|
V.TLT
|
In my view, next week Theralase will announce a post-450 day durable response...
|
|
V.TLT
|
"As TLD-1433 absorbs in green, red, and NIR light in a biological...
|
|
V.TLT
|
Thanks CancerSlayer. I'd guess the Rutherrin was delivered systemically...
|
|
V.TLT
|
I think Theralase is ahead. But there could be any number of clinical trials...
|
|
V.TLT
|
Researchers in every corner of the globe seem aware of what's going on...
|
|
V.TLT
|
Recent advances for enhanced photodynamic therapy: from new mechanisms to...
|
|
V.TLT
|
Ru(II)-Photoactive Agents for Targeting ER Stress and Immunogenic Cell Death ...
|
|
V.TLT
|
Makes sense to me. There may be more than large investor not committed yet...
|
|
V.TLT
|
So you want to bypass first world safety standards for people in poor...
|
|
V.TLT
|
Looks like 18 investors in the first tranche. The second tranche should be...
|
|
V.TLT
|
I may be wrong, but the way I read the last MD&A Theralase plans to do a...
|
|
V.TLT
|
Thanks for the post DJDawg. It all sounds right to me. They have...
|
|
V.TLT
|
>Ahem< that should be non-muscle-invasive bladder cancer Anticancer...
|
|
V.TLT
|
In the blue banner on the top of this page, if you click on the...
|
|
V.TLT
|
According to Roger, if they can raise $5M they will be base shelf eligible...
|